Potential Cardioprotective Effects of Sumac Capsule in Patients With Hyperlipidemia: A Triple-Blind Randomized, Placebo-Controlled Crossover Trial. (19th May 2018)

• Record Type: Journal Article
• Authors: Asgary, Sedigheh; Salehizadeh, Leila; Keshvari, Mahtab; Taheri, Marzieh; Spence, Nicholas D.; Farvid, Maryam S.; Rafieian-Kopaei, Mahmoud; Sarrafzadegan, Nizal
• Is Part Of: Journal of the American College of Nutrition. Volume 37:Number 4(2018)
• Page Start: 286
• Page End: 292
• Publication Date: 2018-05-19
• Subjects: Crossover trial -- flow-mediated dilation -- dyslipidemia -- blood pressure -- Rhus -- sumac; Nutrition -- Periodicals; Nutrition disorders -- Periodicals; 613.2
• DOI: 10.1080/07315724.2017.1394237
• Languages: English
• ISSNs: 0731-5724

Abstract

ABSTRACT: Objective : Alternative medicine and herbal drugs have been taken into account for managing cardiovascular risk factors. Sumac ( Rhus coriaria L.) is rich in biologically active ingredients known to improve cardiovascular health. We investigated the effect of sumac on systolic (SBP) and diastolic (DBP) blood pressure, flow-mediated dilation (FMD), body mass index (BMI), and serum concentrations of lipids and fasting blood sugar (FBS) in participants with hyperlipidemia in a triple-blind randomized placebo- controlled crossover trial. Methods : Thirty adults with dyslipidemia (mild to moderate elevation of plasma total cholesterol and/or triglycerides [TG; total cholesterol ≥ 6.0 mmol/L or TG ≥ 1.7 mmol/L and TG ≤ 5.0 mmol/L]) were assigned randomly to a sumac or a placebo group. Participants in the sumac group received sumac capsules (500 mg/twice daily) for the first 4 weeks, followed by 2 weeks' washout period; the patients were then switched to a 4-week interval and received placebo for 4 weeks in the second period. The placebo group received these treatments in reverse order. FMD, BMI, SBP, DBP, lipids, and FBS were measured at baseline and after each period. Results : Differences between placebo group and sumac group (placebo-sumac) were significantly decreased for BMI (0.21 ± 0.075 kg/m 2 ), SBP (1.87 ± 0.83 mm Hg), DBP (1.32 ± 0.46 mm Hg), and total cholesterol (14.42 ± 4.95 mmol/L) and significantly increased for FMD (−0.23% ± 0.065%). Plasma level of TG did not change significantly across the treatment. Conclusion : Sumac consumption may decrease cardiovascular risk factors in persons with mild to moderate hyperlipidemia.